Strong growth forecast for Asia-Pacific asthma market

The Asia-Pacific (APAC) asthma therapeutics market, which covers India, China, Australia, South Korea and Japan, is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023, representing a compound annual growth rate of 5.4%.

According to business intelligence provider GBI Research’s latest report, this strong growth will be driven by an expanding aging population, increases in air pollution, a promising product pipeline and the launch of first-in-class molecules.

Gautam Arora, an analyst for GBI Research, explains: “There are a number of therapies currently in development for asthma designed to address unmet needs in the market that will, depending on clinician uptake, drive the annual cost of therapy associated with the disease.”